{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:18:38Z","timestamp":1779297518502,"version":"3.51.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Blinatumomab, a bispecific T-cell engager, requires the activity of CD3+ T-cells for tumor lysis. This pooled analysis aimed to re-examine baseline T regulatory cells (Tregs) as a biomarker of blinatumomab efficacy across multiple clinical trials and provide insights into peripheral T-cell dynamics during blinatumomab therapy in hematological malignancies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Tregs and peripheral T-cells were enumerated by fluorescence-activated cell sorting and were statistically evaluated using the Wilcoxon rank-sum test and linear mixed effect modeling, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Comparable baseline percentages of Tregs were observed in responders and non-responders of blinatumomab treatment (N\u2005=\u2005325) in adults with leukemia or lymphoma. Peripheral T-cell count recovery occurred early during blinatumomab dosing, and before blinatumomab-free interval in patients (N\u2005=\u2005233) from 4 clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The pooled analysis revealed that baseline Treg levels do not serve as a predictive marker for blinatumomab response and that there is rapid peripheral T-cell recovery following blinatumomab dosing. These results suggest that patients with varying levels of Tregs can benefit from blinatumomab treatment and that blinatumomab-free intervals of 7 days may suffice in blinatumomab treatment regimens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf137","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T06:00:02Z","timestamp":1749880802000},"source":"Crossref","is-referenced-by-count":1,"title":["Pooled biomarker analysis of the association of baseline T regulatory cells with response and T-cell recovery profiles with blinatumomab treatment"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5647-4782","authenticated-orcid":false,"given":"Yuliya","family":"Katlinskaya","sequence":"first","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharat","family":"Panwar","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gordon","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Naegele","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH , Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Klinger","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH , Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH , Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"2025061401595667800_CIT0001","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.molonc.2012.01.010","article-title":"Cancer biomarkers","volume":"6","author":"Henry","year":"2012","journal-title":"Mol Oncol"},{"key":"2025061401595667800_CIT0002","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3978\/j.issn.2218-676X.2015.06.04","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Transl Cancer Res"},{"key":"2025061401595667800_CIT0003","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"key":"2025061401595667800_CIT0004","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41375-020-01089-x","article-title":"Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia","volume":"35","author":"Wei","year":"2021","journal-title":"Leukemia"},{"key":"2025061401595667800_CIT0005","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"2025061401595667800_CIT0006","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"2025061401595667800_CIT0007","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"2025061401595667800_CIT0008","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"2025061401595667800_CIT0009","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025061401595667800_CIT0010","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1182\/blood-2021-152822","article-title":"A phase 1b study of blinatumomab including subcutaneous administration in relapsed \/ refractory (R\/R) indolent non Hodgkin\u2019s lymphoma (NHL)","volume":"138","author":"Rossi","year":"2021","journal-title":"Blood"},{"key":"2025061401595667800_CIT0011","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2025061401595667800_CIT0012","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/10428194.2022.2064981","article-title":"Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL","volume":"63","author":"Katz","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2025061401595667800_CIT0013","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/16078454.2022.2111992","article-title":"Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study","volume":"27","author":"Zhou","year":"2022","journal-title":"Hematology"},{"key":"2025061401595667800_CIT0014","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.exphem.2021.06.005","article-title":"Relationship of T- and B-cell kinetics to clinical response in patients with relapsed\/refractory non-Hodgkin lymphoma treated with blinatumomab","volume":"100","author":"Nagele","year":"2021","journal-title":"Exp Hematol"},{"key":"2025061401595667800_CIT0015","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025061401595667800_CIT0016","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4612-5931-2_7","article-title":"Kolmogorov-Smirnov Two-Sample Tests","author":"Pratt","year":"1981","journal-title":"Concepts of Nonparametric Theory"},{"key":"2025061401595667800_CIT0017","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2307\/3001968","article-title":"Individual comparisons by ranking methods","volume":"1","author":"Wilcoxon","year":"1945","journal-title":"Biometrics Bulletin"},{"key":"2025061401595667800_CIT0018","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Stat Soc Ser B: Stat Methodol"},{"key":"2025061401595667800_CIT0019","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed- effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Soft"},{"key":"2025061401595667800_CIT0020","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"2025061401595667800_CIT0021","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"blinatumomab, a bispecific T-cell engager (bite((r))) for cd-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf137\/63488991\/oyaf137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf137\/63488991\/oyaf137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T06:00:04Z","timestamp":1749880804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf137\/8162466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf137","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf137"}}